Trial Profile
Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Sapropterin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 04 May 2018 New trial record
- 26 Apr 2018 Primary endpoint (Flow-Mediated Dilation (FMD)) has been met, according to results published in the Chest.
- 26 Apr 2018 Results (n=34) assessing overall objective of this proposal is to identify the role of NO bioavailability in contributing to vascular endothelial dysfunction in patients with COPD and to provide insight into the molecular mechanisms involved, were published in the Chest.